Bausch & Lomb
BLCONext catalyst
Rifaximin SSD IR
Dementia Alzheimer Type
Get an email about BLCO's next catalysts
Track Bausch & Lomb (BLCO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Rifaximin SSD IR Phase 2 Est. Readout (RIDE)
Estimated primary completion for Rifaximin SSD IR trial (NCT06718686) in Dementia Alzheimer Type. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Bausch & Lomb (since 2010 stylized as Bausch + Lomb) is a Canadian eye health products company based in Vaughan, Ontario, Canada. It is one of the world's largest suppliers of contact lenses, lens care products, pharmaceuticals, intraocular lenses, and other eye surgery products. The company was founded in Rochester, New York, in 1853 by optician John Bausch and cabinet maker turned financial backer Henry Lomb. Until its sale in 2013, Bausch + Lomb was one of the oldest continually operating companies in the United States.
WebsiteKetoNaph
Allergic Conjunctivitis
Timolol
Open-Angle Glaucoma
Loteprednol and tobramycin
Conjunctivitis
Prednisolone and Tobramycin
Eye Infections
Azopt
Glaucoma
Brimonidine Tartrate/Ketotifen Fumarate Ophthalmic Solution (Combo)
Allergic Conjunctivitis
Pred Forte
Cataract
Besifloxacin
Acute Bacterial Conjunctivitis
BTOS-HA
Ocular Redness
Bepreve (bepotastine besilate ophthalmic solution)
Allergic Conjunctivitis
IDP-118 Lotion
Psoriasis
IDP-124 Lotion
Atopic Dermatitis
Olopatadine
Seasonal Allergic Conjunctivitis
Budesonide MMX®
Ulcerative Colitis
1,2 dithiolane 3 valeric acid
Diabetes Mellitus
Methylnaltrexone
Post-Operative Ileus (POI)
tramadol HCl ER; celecoxib
Chronic Pain
SC Methylnaltrexone (MNTX)
Terminal Illness
pegylated interferon alfa-2b
Chronic Hepatitis C
Retigabine
Seizures
budesonide-MMX®
Ulcerative Colitis
Infergen (Interferon Alfacon-1, CIFN) + Ribavirin for up to 48 wks
Chronic Hepatitis C
IDP-126 Gel
Acne Vulgaris
Brimonidine tartrate ophthalmic
Seasonal Allergic Conjunctivitis
SC Methylnaltrexone
Advanced Illness Patients With Opioid Induced Constipation
5-ASA
Ulcerative Colitis
IDP-120 Gel
Acne Vulgaris
Zaditor®
Allergic Conjunctivitis
Bromfenac Ophthalmic Solution B
Dry Eye Syndrome
Viramidine
Chronic Hepatitis C
Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Hyperemia
Ketotifen fumarate ophthalmic
Seasonal Allergic Conjunctivitis
Bepotastine Besilate Ophthalmic
Allergic Conjunctivitis
Loteprednol Etabonate Ophthalmic Gel dosed BID
Cataract
Tramadol HCl ER
Chronic Pain
Granulated mesalamine
Ulcerative Colitis
Methylnaltrexone (MOA-728)
Post Operative Bowel Dysfunction
N-methylnaltrexone bromide (MOA-728)
Constipation
Rifaximin SSD
Overt Hepatic Encephalopathy
Omeprazole/sodium bicarbonate
Gastric Acid
Loteprednol Etabonate Gel (BID)
Inflammation
Bromfenac Ophthalmic Solution
Pain
brinzolamide ophthalmic
Glaucoma
Loteprednol Etabonate Ophthalmic
Ocular Inflammation
BOL-303259-X
Ocular Hypertension
Bromfenac
Postoperative Complications
Loteprednol etabonate
Cataract
Besivance
Bacterial Conjunctivitis
Loteprednol Etabonate Gel (TID)
Inflammation
EM-100
Allergic Conjunctivitis
Brimonidine Tartrate
Hyperemia
Latanoprostene bunod
Glaucoma
Bepotastine besilate
Seasonal Allergic Rhinitis
Ketotifen/naphazoline
Allergic Conjunctivitis
Loteprednol Etabonate Ophthalmic Gel dosed TID
Cataract
Bromfenac Ophthalmic Solution A
Dry Eye Syndrome
Brimonidine Tartrate/Ketotifen Fumarate Ophthalmic
Seasonal Allergic Conjunctivitis
Ecabet
Dry Eye Syndromes
Vitrase
Pain
fluocinolone acetonide intravitreal implant
Non-infectious Uveitis
Mapracorat
Cataract
NOV03
Dry Eye Disease (DED)
T-PRED
Cataract
Brimonidine tartrate ophthalmic solution preservative-free formulation
Ocular Redness
Brimonidine tartrate/ketotifen fumarate
Allergic Conjunctivitis
ISV-403
Acute Bacterial Conjunctivitis
Sodium Fluorescein
Hyperemia
Naphazoline
Allergic Conjunctivitis
fluocinolone acetonide
Diabetic Macular Edema
Bepreve
Conjunctivitis, Allergic
Topical Ocular BL1332 low dose
Pain, Postoperative
Methylnaltrexone bromide
Opioid-induced Constipation
lidamycin phosphate and benzoyl peroxide/combination
Actinic Keratosis
Rifaximin 550 milligrams (MG)
Alzheimer's Disease
Bepotastine Besilate Nasal
Seasonal Allergic Rhinitis
PF-03187207 and Latanoprost Vehicle
Primary Open Angle Glaucoma
bromfenac ophthalmic
Dry Eye Disease
Soothe® Lubricant Eye Drops
Keratoconjunctivitis Sicca
bepotastine besilate nasal product - low dose
Seasonal Allergic Rhinitis
Bepotastine besilate-fluticasone propionate
Seasonal Allergic Rhinitis
BOL-303242-X ophthalmic suspension AM
Dry Eye Syndrome
WB007
Glaucoma, Primary Open Angle
SAN-300 QOW
Rheumatoid Arthritis
Bepotastine besilate formulation
Seasonal Allergic Rhinitis
Rifaximin SSD IR
Dementia Alzheimer Type
Rifaximin SSD SER
Liver Cirrhosis
BOL-303242-X ophthalmic suspension PM
Dry Eye Syndrome
BL1107 High dose
Glaucoma
Restasis
Keratoconjunctivitis Sicca
ecabet ophthalmic solution
Dry Eye Disease
BOL-303242-X
Cataract
Rifaximin SSD 80mgIR/80mgSER tablet
Liver Cirrhosis
High Dose MT-1303
Ulcerative Colitis
Loteprednol etabonate base (QID)
Allergic Conjunctivitis
PF-03187207
Primary Open Angle Glaucoma
Topical Ocular BL1332 high dose
Pain, Postoperative
Latanoprost
Intraocular Pressure
BL1107 Low dose
Glaucoma
Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
Dry Eye Disease
bepotastine besilate nasal product - medium dose
Seasonal Allergic Rhinitis
Loteprednol etabonate base (QD)
Allergic Conjunctivitis
bepotastine besilate ophthalmic solution
Allergic Conjunctivitis
bepotastine besilate nasal product - high dose
Seasonal Allergic Rhinitis
MT-1303
Ulcerative Colitis
BOL-303242-X ophthalmic
Dry Eye Syndrome
Loteprednol etabonate base (BID)
Allergic Conjunctivitis
Lotemax
Keratoconjunctivitis Sicca
Loteprednol etabonate suspension
Allergic Conjunctivitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KetoNaph | Phase 3 | Allergic Conjunctivitis | - | - |
Timolol | Phase 3 | Open-Angle Glaucoma | - | - |
Loteprednol and tobramycin | Phase 3 | Conjunctivitis | - | - |
Prednisolone and Tobramycin | Phase 3 | Eye Infections | - | - |
Azopt | Phase 3 | Glaucoma | - | - |
Brimonidine Tartrate/Ketotifen Fumarate Ophthalmic Solution (Combo) | Phase 3 | Allergic Conjunctivitis | - | - |
Pred Forte | Phase 3 | Cataract | - | - |
Besifloxacin | Phase 3 | Acute Bacterial Conjunctivitis | - | - |
BTOS-HA | Phase 3 | Ocular Redness | - | - |
Bepreve (bepotastine besilate ophthalmic solution) | Phase 3 | Allergic Conjunctivitis | - | - |
IDP-118 Lotion | Phase 3 | Psoriasis | - | - |
IDP-124 Lotion | Phase 3 | Atopic Dermatitis | - | - |
Olopatadine | Phase 3 | Seasonal Allergic Conjunctivitis | - | - |
Budesonide MMX® | Phase 3 | Ulcerative Colitis | - | - |
1,2 dithiolane 3 valeric acid | Phase 3 | Diabetes Mellitus | - | - |
Methylnaltrexone | Phase 3 | Post-Operative Ileus (POI) | - | - |
tramadol HCl ER; celecoxib | Phase 3 | Chronic Pain | - | - |
SC Methylnaltrexone (MNTX) | Phase 3 | Terminal Illness | - | - |
pegylated interferon alfa-2b | Phase 3 | Chronic Hepatitis C | - | - |
Retigabine | Phase 3 | Seizures | - | - |
budesonide-MMX® | Phase 3 | Ulcerative Colitis | - | - |
Infergen (Interferon Alfacon-1, CIFN) + Ribavirin for up to 48 wks | Phase 3 | Chronic Hepatitis C | - | - |
IDP-126 Gel | Phase 3 | Acne Vulgaris | - | - |
Brimonidine tartrate ophthalmic | Phase 3 | Seasonal Allergic Conjunctivitis | - | - |
SC Methylnaltrexone | Phase 3 | Advanced Illness Patients With Opioid Induced Constipation | - | - |
5-ASA | Phase 3 | Ulcerative Colitis | - | - |
IDP-120 Gel | Phase 3 | Acne Vulgaris | - | - |
Zaditor® | Phase 3 | Allergic Conjunctivitis | - | - |
Bromfenac Ophthalmic Solution B | Phase 3 | Dry Eye Syndrome | - | - |
Viramidine | Phase 3 | Chronic Hepatitis C | - | - |
Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Phase 3 | Hyperemia | - | - |
Ketotifen fumarate ophthalmic | Phase 3 | Seasonal Allergic Conjunctivitis | - | - |
Bepotastine Besilate Ophthalmic | Phase 3 | Allergic Conjunctivitis | - | - |
Loteprednol Etabonate Ophthalmic Gel dosed BID | Phase 3 | Cataract | - | - |
Tramadol HCl ER | Phase 3 | Chronic Pain | - | - |
Granulated mesalamine | Phase 3 | Ulcerative Colitis | - | - |
Methylnaltrexone (MOA-728) | Phase 3 | Post Operative Bowel Dysfunction | - | - |
N-methylnaltrexone bromide (MOA-728) | Phase 3 | Constipation | - | - |
Rifaximin SSD | Phase 3 | Overt Hepatic Encephalopathy | - | - |
Omeprazole/sodium bicarbonate | Phase 3 | Gastric Acid | - | - |
Loteprednol Etabonate Gel (BID) | Phase 3 | Inflammation | - | - |
Bromfenac Ophthalmic Solution | Phase 3 | Pain | - | - |
brinzolamide ophthalmic | Phase 3 | Glaucoma | - | - |
Loteprednol Etabonate Ophthalmic | Phase 3 | Ocular Inflammation | - | - |
BOL-303259-X | Phase 3 | Ocular Hypertension | - | - |
Bromfenac | Phase 3 | Postoperative Complications | - | - |
Loteprednol etabonate | Phase 3 | Cataract | - | - |
Besivance | Phase 3 | Bacterial Conjunctivitis | - | - |
Loteprednol Etabonate Gel (TID) | Phase 3 | Inflammation | - | - |
EM-100 | Phase 3 | Allergic Conjunctivitis | - | - |
Brimonidine Tartrate | Phase 3 | Hyperemia | - | - |
Latanoprostene bunod | Phase 3 | Glaucoma | - | - |
Bepotastine besilate | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Ketotifen/naphazoline | Phase 3 | Allergic Conjunctivitis | - | - |
Loteprednol Etabonate Ophthalmic Gel dosed TID | Phase 3 | Cataract | - | - |
Bromfenac Ophthalmic Solution A | Phase 3 | Dry Eye Syndrome | - | - |
Brimonidine Tartrate/Ketotifen Fumarate Ophthalmic | Phase 3 | Seasonal Allergic Conjunctivitis | - | - |
Ecabet | Phase 3 | Dry Eye Syndromes | - | - |
Vitrase | Phase 3 | Pain | - | - |
fluocinolone acetonide intravitreal implant | Phase 3 | Non-infectious Uveitis | - | - |
Mapracorat | Phase 3 | Cataract | - | - |
NOV03 | Phase 3 | Dry Eye Disease (DED) | - | - |
T-PRED | Phase 3 | Cataract | - | - |
Brimonidine tartrate ophthalmic solution preservative-free formulation | Phase 3 | Ocular Redness | - | - |
Brimonidine tartrate/ketotifen fumarate | Phase 3 | Allergic Conjunctivitis | - | - |
ISV-403 | Phase 3 | Acute Bacterial Conjunctivitis | - | - |
Sodium Fluorescein | Phase 3 | Hyperemia | - | - |
Naphazoline | Phase 3 | Allergic Conjunctivitis | - | - |
fluocinolone acetonide | Phase 3 | Diabetic Macular Edema | - | - |
Bepreve | Phase 3 | Conjunctivitis, Allergic | - | - |
Topical Ocular BL1332 low dose | Phase 2 | Pain, Postoperative | - | - |
Methylnaltrexone bromide | Phase 2 | Opioid-induced Constipation | - | - |
lidamycin phosphate and benzoyl peroxide/combination | Phase 2 | Actinic Keratosis | - | - |
Rifaximin 550 milligrams (MG) | Phase 2 | Alzheimer's Disease | - | - |
Bepotastine Besilate Nasal | Phase 2 | Seasonal Allergic Rhinitis | - | - |
PF-03187207 and Latanoprost Vehicle | Phase 2 | Primary Open Angle Glaucoma | - | - |
bromfenac ophthalmic | Phase 2 | Dry Eye Disease | - | - |
Soothe® Lubricant Eye Drops | Phase 2 | Keratoconjunctivitis Sicca | - | - |
bepotastine besilate nasal product - low dose | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Bepotastine besilate-fluticasone propionate | Phase 2 | Seasonal Allergic Rhinitis | - | - |
BOL-303242-X ophthalmic suspension AM | Phase 2 | Dry Eye Syndrome | - | - |
WB007 | Phase 2 | Glaucoma, Primary Open Angle | - | - |
SAN-300 QOW | Phase 2 | Rheumatoid Arthritis | - | - |
Bepotastine besilate formulation | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Rifaximin SSD IR | Phase 2 | Dementia Alzheimer Type | - | - |
Rifaximin SSD SER | Phase 2 | Liver Cirrhosis | - | - |
BOL-303242-X ophthalmic suspension PM | Phase 2 | Dry Eye Syndrome | - | - |
BL1107 High dose | Phase 2 | Glaucoma | - | - |
Restasis | Phase 2 | Keratoconjunctivitis Sicca | - | - |
ecabet ophthalmic solution | Phase 2 | Dry Eye Disease | - | - |
BOL-303242-X | Phase 2 | Cataract | - | - |
Rifaximin SSD 80mgIR/80mgSER tablet | Phase 2 | Liver Cirrhosis | - | - |
High Dose MT-1303 | Phase 2 | Ulcerative Colitis | - | - |
Loteprednol etabonate base (QID) | Phase 2 | Allergic Conjunctivitis | - | - |
PF-03187207 | Phase 2 | Primary Open Angle Glaucoma | - | - |
Topical Ocular BL1332 high dose | Phase 2 | Pain, Postoperative | - | - |
Latanoprost | Phase 2 | Intraocular Pressure | - | - |
BL1107 Low dose | Phase 2 | Glaucoma | - | - |
Lifitegrast/Perfluorohexyloctane Fixed Dose Combination | Phase 2 | Dry Eye Disease | - | - |
bepotastine besilate nasal product - medium dose | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Loteprednol etabonate base (QD) | Phase 2 | Allergic Conjunctivitis | - | - |
bepotastine besilate ophthalmic solution | Phase 2 | Allergic Conjunctivitis | - | - |
bepotastine besilate nasal product - high dose | Phase 2 | Seasonal Allergic Rhinitis | - | - |
MT-1303 | Phase 2 | Ulcerative Colitis | - | - |
BOL-303242-X ophthalmic | Phase 2 | Dry Eye Syndrome | - | - |
Loteprednol etabonate base (BID) | Phase 2 | Allergic Conjunctivitis | - | - |
Lotemax | Phase 2 | Keratoconjunctivitis Sicca | - | - |
Loteprednol etabonate suspension | Phase 2 | Allergic Conjunctivitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Bausch & Lomb's drug pipeline?→
CatalystAlert tracks 108 drug candidates in Bausch & Lomb's (BLCO) pipeline across Phase 3, Phase 2. Its lead program is 1,2 dithiolane 3 valeric acid (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bausch & Lomb's next FDA catalyst?→
Bausch & Lomb's (BLCO) next tracked catalyst is a Phase 2 readout expected Q4 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BLCO biotech catalysts?→
Add BLCO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bausch & Lomb's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.